| 摘要 |
The invention concerns the use of nucleotide analogues, defined as molecules acceptable as substrate of the reverse-transcription response and enabling the addition of at least one supplementary nucleotide to the polynucleotide chain during the reverse transcription to affect and/or to control the fidelity and execution of the reverse transcription. The invention also concerns a pharmaceutical composition containing said nucleotide analogues preferably selected among dUTP, dITP, C7dGTP and C7dATP or characterised in that they have modified bases 6H, 8H-3,4-dihydropyrimido[4,5c][1,2]oxazin-7-one (P) and N methoxy-2,6-diaminopurine (K) alone or mixed with 3'-azido-3'deoxythimidine(AZT), 2',3'-dideoxyinosine-(ddI), 2',3'-dideoxycytidine (ddC), (-)2',3'-dideoxy-3'-theacytidine (3TC), 2',3'-didehydro-2',3'-dideoxythymidine (d4T) and (-)2'-deoxy-5-fluoro-3'-theacytidine (FTC), TIBO (tetrahydroimidazo-(4,5,1-1,jk) (1,4)-benzodiapezine-2-(1H)-one, HEPT (1-[(2-hydroxyethoxy)-methyl]-6-phenylthiothymine), TSAO([2', 5'-bis-O-(tert-butylmethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-dioxide), alpha -APA (alpha-anilinophenylacetamide), neviparine, BAHP (bis(etheroaryl)-piperazine) or phosphonoformic acid (PFA), indinavir, saquinavir.
|
